M&A Deal Summary |
|
|---|---|
| Date | 2023-04-18 |
| Target | BELLUS Health |
| Sector | Life Science |
| Buyer(s) | GSK |
| Deal Type | Add-on Acquisition |
| Deal Value | 2.0B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1715 |
| Sector | Life Science |
| Employees | 68,629 |
| Revenue | 31.4B GBP (2024) |
GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 30 of 35 |
| Sector: Life Science M&A | 24 of 28 |
| Type: Add-on Acquisition M&A Deals | 22 of 25 |
| State: Quebec M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Size (of disclosed) | 8 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-31 |
Affinivax
Cambridge, Massachusetts, United States Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines, using its patented biotin-rhizavidin binding approach to optimize the body’s protective immune response to address infectious and other immune-mediated diseases. Affinivax is based in Cambridge, Massachusetts. |
Buy | $2.1B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-01-09 |
Aiolos Bio
San Francisco, California, United States Aiolos Bio is a clinical-stage, private, biopharmaceutical company dedicated to revolutionising the treatment landscape for respiratory disease. Aiolos Bio is based in San Francisco, California. |
Buy | $1.4B |